Artera, Atlantic Health deploy AI agents for colonoscopy patient outreach
California-based Artera , an agentic AI company focused on patient communication, has partnered with health system Atlantic Health to deploy AI agents for colonoscopy patient outreach. Atlantic Health uses Artera AI agents to automate pre-procedure patient calls a week before their procedure, encourage patients to review preparation materials and answer more than 80 Atlantic Health-approved clinical and operational questions in multiple languages.
Photo: bymuratdeniz/Getty Images
California-based Artera, an agentic AI company focused on patient communication, has partnered with health system Atlantic Health to deploy AI agents for colonoscopy patient outreach.
Atlantic Health uses Artera AI agents to automate pre-procedure patient calls a week before their procedure, encourage patients to review preparation materials and answer more than 80 Atlantic Health-approved clinical and operational questions in multiple languages.
The not-for-profit health system operates in New Jersey, Pennsylvania and the New York metropolitan area, and the partnership marks its first use of an AI agent for outbound patient communications to support preventive care.
"It's great to see a team like Atlantic Health show what's possible when you stop talking about AI and start using it. They've moved quickly to put AI where it actually matters for patients. We love partnering with teams to think big, move fast and scale impact," Guillaume de Zwirek, CEO and cofounder of Artera, told MobiHealthNews.
THE LARGER TREND
In March, Artera announced the appointment of Damon Lanphear as its new chief technology officer. Lanphear formerly held leadership positions across three business units at Amazon – Amazon Web Services (AWS) Snow, AWS Managed Services and Amazon Devices – and oversaw technical strategy for Kindle and Scribe devices.
Lanphear sat down with MobiHealthNews to discuss how he plans to apply his Amazon experience to advance Artera's technology strategy.
In December, the company secured $65 million in growth investment.
Last August, Artera was granted de novo authorization by the FDA for ArteraAI Prostate, an AI-enabled software tool designed to help clinicians make risk-based decisions for patients with non-metastatic prostate cancer. The company received Breakthrough Device Designation by the FDA the month before for the same product.
In 2024, Artera secured $20 million in capital, one year after its public launch with $90 million in funding.
Tags:
MobiHealthNews
https://www.mobihealthnews.com/news/artera-atlantic-health-deploy-ai-agents-colonoscopy-patient-outreachSign in to highlight and annotate this article
Conversation starters
Daily AI Digest
Get the top 5 AI stories delivered to your inbox every morning.
.jpg)
Knowledge Map
Connected Articles — Knowledge Graph
This article is connected to other articles through shared AI topics and tags.
Discussion
Sign in to join the discussion
No comments yet — be the first to share your thoughts!